{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:44:59Z","timestamp":1786985099756,"version":"build-2736575974"},"reference-count":89,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.berh.2025.102090","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T03:49:11Z","timestamp":1758599351000},"page":"102090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pipeline treatments on psoriatic disease"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6782-8924","authenticated-orcid":false,"given":"Andr\u00e9 L.","family":"Ribeiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro L.","family":"Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Micheroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela B.","family":"Tovar-Batisdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Angeliki","family":"Gkini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Proft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.berh.2025.102090_bib1","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","article-title":"Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis","volume":"74","author":"Mease","year":"2014","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.berh.2025.102090_bib2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2025.102090_bib3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.berh.2025.102090_bib4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"23","key":"10.1016\/j.berh.2025.102090_bib5","first-page":"S0149","article-title":"Pharmacologic treatment strategies in psoriatic arthritis","volume":"14","author":"Ayan","year":"2023","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.berh.2025.102090_bib6","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keaa030","article-title":"Remission and low disease activity in psoriatic arthritis publications: a systematic literature review with meta-analysis","volume":"59","author":"Hag\u00e8ge","year":"2020","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.berh.2025.102090_bib7","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","article-title":"Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis","volume":"72","author":"Tillett","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2025.102090_bib8","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","volume":"74","author":"Haroon","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"10.1016\/j.berh.2025.102090_bib9","first-page":"S0149","article-title":"Challenges in the management of psoriatic arthritis in Latin America: a systematic review","volume":"15","author":"Ribeiro","year":"2023","journal-title":"Clin Ther"},{"key":"10.1016\/j.berh.2025.102090_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/rap\/rkae074","article-title":"Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals","author":"Ribeiro","year":"2024","journal-title":"Rheum Adv Prac"},{"issue":"1","key":"10.1016\/j.berh.2025.102090_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003809","article-title":"Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project","volume":"10","author":"Singla","year":"2024","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.berh.2025.102090_bib12","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1007\/s10067-023-06605-9","article-title":"Difficult to treat psoriatic arthritis - how should we manage?","volume":"42","author":"Kumthekar","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102090_bib13","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.berh.2025.102090_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2025.102090_bib15","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13555-021-00596-8","article-title":"Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with janus kinase 1\/2\/3 inhibitors","volume":"11","author":"Chimalakonda","year":"2021","journal-title":"Dermatol Ther"},{"issue":"14","key":"10.1016\/j.berh.2025.102090_bib16","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2025.102090_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 program fOr evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102090_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.berh.2025.102090_bib19","author":"Bristol-Myers"},{"issue":"6","key":"10.1016\/j.berh.2025.102090_bib20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2025.102090_bib21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/acr.25333","article-title":"Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: results from a randomized phase 2 trial","volume":"76","author":"Strand","year":"2024","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2025.102090_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2025.05.014","article-title":"Pharmacological characterization of zasocitinib (TAK-279): an oral, highly selective and potent allosteric TYK2 inhibitor","author":"Mehrotra","year":"2025","journal-title":"J Invest Dermatol"},{"issue":"15","key":"10.1016\/j.berh.2025.102090_bib23","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","article-title":"Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279","volume":"66","author":"Leit","year":"2023","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.berh.2025.102090_bib24","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.berh.2025.102090_bib25","author":"Takeda","year":"2024","journal-title":"clinicaltrials gov"},{"key":"10.1016\/j.berh.2025.102090_bib26","article-title":"Multi-center, randomized, double-blind, and placebo-controlled phase 3 study to evaluate the efficacy and safety of zasocitinib (TAK-279) in subjects with active psoriatic arthritis stratified by prior biologic use (LATITUDE-PsA-3002) [Internet]","author":"Takeda","year":"2024","journal-title":"clinicaltrials gov"},{"issue":"0","key":"10.1016\/j.berh.2025.102090_bib27","article-title":"Highly selective tyrosine kinase 2 inhibition with Zasocitinib (TAK-279), improves outcomes in patients with active psoriatic arthritis: a randomized phase 2b study","volume":"0","author":"Kivitz","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102090_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110434","article-title":"Recent progress on tyrosine kinase 2 JH2 inhibitors","volume":"121","author":"Deng","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"10.1016\/j.berh.2025.102090_bib29","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70094","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design","volume":"17","author":"Ucpinar","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.berh.2025.102090_bib30","author":"Blauvelt"},{"key":"10.1016\/j.berh.2025.102090_bib32","article-title":"A multicenter, randomized, double-blind, placebo and active comparator controlled phase 3 study to evaluate the efficacy and safety of ESK-001 in patients with moderate to severe plaque psoriasis (ONWARD1)","year":"2025","journal-title":"clinicaltrials gov"},{"key":"10.1016\/j.berh.2025.102090_bib33","article-title":"A multicenter, randomized, double-blind, placebo and active comparator controlled phase 3 study in patients with moderate to severe plaque psoriasis to evaluate the efficacy and safety of ESK-001 (ONWARD2)","year":"2025","journal-title":"clinicaltrials gov"},{"key":"10.1016\/j.berh.2025.102090_bib34","unstructured":"Zhang X, et al. Efficacy and safety of a highly selective oral TYK2 inhibitor, ICP-488, in patients with moderate-to-severe plaque psoriasis: a phase II, randomized, double-blinded, placebo-controlled trial. Abstract 66757, LBA session 2, 2025 AAD Annual meeting, 07\u201311 march, Orlando, FL, USA."},{"key":"10.1016\/j.berh.2025.102090_bib36","article-title":"A multicenter, randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of oral ICP-488 in patients with moderate to severe plaque psoriasis","year":"2025","journal-title":"clinicaltrials gov"},{"issue":"12","key":"10.1016\/j.berh.2025.102090_bib37","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"8","key":"10.1016\/j.berh.2025.102090_bib38","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102090_bib39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bjd\/ljad098","article-title":"Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study","volume":"189","author":"Landis","year":"2023","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2025.102090_bib40","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41584-024-01093-w","article-title":"TYK2: an emerging therapeutic target in rheumatic disease","volume":"20","author":"Morand","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102090_bib41","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.berh.2025.102090_bib42","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.berh.2025.102090_bib43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.berh.2025.102090_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.berh.2025.102090_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241210305","article-title":"Pathogenic role of IL-17 and therapeutic targeting of IL-17F in psoriatic arthritis and spondyloarthropathies","volume":"24","author":"S\u00e1nchez-Rodr\u00edguez","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.berh.2025.102090_bib46","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/bjd\/ljae062","article-title":"A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis","volume":"191","author":"Cai","year":"2024","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102090_bib47","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40265-024-02125-1","article-title":"Xeligekimab: first approval","volume":"85","author":"Blair","year":"2025","journal-title":"Drugs"},{"key":"10.1016\/j.berh.2025.102090_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.berh.2025.102090_bib49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/bjd\/ljad186","article-title":"Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment","volume":"189","author":"Gerdes","year":"2023","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102090_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.47360\/1995-4484-2021-47-55","article-title":"Efficacy of netakimab in key psoriatic arthritis domains: 54-Week results from the phase III BCD-085-8\/PATERA study","volume":"59","author":"Korotaeva","year":"2021","journal-title":"Rheumatol Sci Prac"},{"issue":"2","key":"10.1016\/j.berh.2025.102090_bib51","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102090_bib53","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5114\/reum.2021.105455","article-title":"Brodalumab in the treatment of psoriatic arthritis \u2013 the latest reports","volume":"59","author":"Banaszczyk","year":"2021","journal-title":"Reumatologia"},{"issue":"10284","key":"10.1016\/j.berh.2025.102090_bib54","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2025.102090_bib55","unstructured":"Efficacy and safety of sonelokimab, a novel IL-17A- and IL-17F-Inhibiting nanobody, in patients with active PsA: 24-week results from a global, randomized, double-blind, placebo-controlled phase 2 trial [Internet]. ACR Meet Abstr [cited 2025 Mar 7]. Available from: https:\/\/acrabstracts.org\/abstract\/efficacy-and-safety-of-sonelokimab-a-novel-il-17a-and-il-17f-inhibiting-nanobody-in-patients-with-active-psa-24-week-results-from-a-global-randomized-double-blind-placebo-controlled-phase-2-tri\/."},{"key":"10.1016\/j.berh.2025.102090_bib56","unstructured":"Vunakizumab in patients with active psoriatic arthritis: a multicenter, randomized, double-blind, placebo-controlled, phase 2 study [Internet]. ACR Meet Abstr [cited 2025 Mar 7]. Available from: https:\/\/acrabstracts.org\/abstract\/vunakizumab-in-patients-with-active-psoriatic-arthritis-a-multicenter-randomized-double-blind-placebo-controlled-phase-2-study\/."},{"key":"10.1016\/j.berh.2025.102090_bib57","unstructured":"Achievement of different treatment targets with izokibep demonstrates efficacy benefits in patients with active psoriatic arthritis: results from a 16-Week randomized, placebo-controlled phase 2 clinical trial [Internet]. ACR Meet Abstr [cited 2025 Mar 7]. Available from: https:\/\/acrabstracts.org\/abstract\/achievement-of-different-treatment-targets-with-izokibep-demonstrates-efficacy-benefits-in-patients-with-active-psoriatic-arthritis-results-from-a-16-week-randomized-placebo-controlled-phase-2-clini\/."},{"key":"10.1016\/j.berh.2025.102090_bib58","article-title":"Next-generation Anti-IL-17 agents for psoriatic disease: a pipeline review","author":"Kim","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.berh.2025.102090_bib59","unstructured":"DICE THERAPEUTICS [Internet]. [cited 2025 Mar 7]. Pipeline Available from: https:\/\/www.dicetherapeutics.com\/pipeline\/."},{"key":"10.1016\/j.berh.2025.102090_bib61","article-title":"A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis","year":"2025","journal-title":"clinicaltrials gov"},{"key":"10.1016\/j.berh.2025.102090_bib62","unstructured":"Eli lilly rolls the dice, axing psoriasis prospect and pivoting to follow-up 1 year after $2.4B buyout Fierce Biotech [Internet]. [cited 2025 Apr 7]. Available from: https:\/\/www.fiercebiotech.com\/biotech\/eli-lilly-rolls-dice-axing-psoriasis-prospect-and-pivoting-follow-1-year-after-24b-buyout."},{"key":"10.1016\/j.berh.2025.102090_bib63","article-title":"A phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study of LY4100511 (DC-853) for the treatment of adult participants with Moderate-to severe plaque psoriasis","year":"2025","journal-title":"clinicaltrials gov"},{"key":"10.1016\/j.berh.2025.102090_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1331217","article-title":"IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy","volume":"15","author":"Krueger","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.berh.2025.102090_bib65","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.berh.2025.102090_bib66","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"10091","key":"10.1016\/j.berh.2025.102090_bib68","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.berh.2025.102090_bib69","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102090_bib71","article-title":"A phase III, randomized, double-blind, placebo-controlled study to demonstrate the efficacy and safety of tildrakizumab in Anti-TNF na\u00efve subjects with active psoriatic arthritis II (INSPIRE 2)","year":"2025","journal-title":"clinicaltrials gov"},{"key":"10.1016\/j.berh.2025.102090_bib72","article-title":"A phase III, randomized, double-blind, single-dose, placebo-controlled study to demonstrate the efficacy and safety of tildrakizumab in subjects with active psoriatic arthritis I (INSPIRE 1)","year":"2025","journal-title":"clinicaltrials gov"},{"issue":"1","key":"10.1016\/j.berh.2025.102090_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-67371-5","article-title":"JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans","volume":"14","author":"Fourie","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.berh.2025.102090_bib74","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral Interleukin-23\u2013Receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N Engl J Med"},{"issue":"Supplement_3","key":"10.1016\/j.berh.2025.102090_bib76","article-title":"P130 ORKA-001: a novel extended half-life monoclonal antibody targeting IL-23 with the potential to improve upon currently available therapies for psoriasis","volume":"191","year":"2024","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.berh.2025.102090_bib77","article-title":"Oruka therapeutics, inc. Phase 1, first-in-human, double-blind, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and pharmacokinetics, of ORKA-001 in healthy participants","year":"2024","journal-title":"clinicaltrials gov"},{"key":"10.1016\/j.berh.2025.102090_bib78","article-title":"A phase 2a, multicenter, randomized, double-blind study evaluating the efficacy and safety of subcutaneously administered guselkumab and golimumab combination therapy in participants with active psoriatic arthritis","year":"2025","journal-title":"clinicaltrials gov"},{"issue":"4","key":"10.1016\/j.berh.2025.102090_bib79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.berh.2025.102090_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.berh.2025.102090_bib81","unstructured":"Combination of biological and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis - ACR Meet Abstr, [Internet]. [cited 2024 Sep 29]. Available from: https:\/\/acrabstracts.org\/abstract\/combination-of-biological-and-targeted-synthetic-disease-modifying-antirheumatic-drugs-in-psoriatic-arthritis\/."},{"key":"10.1016\/j.berh.2025.102090_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103038","article-title":"Fecal microbiota transplantation: emerging applications in autoimmune diseases","volume":"141","author":"Yang","year":"2023","journal-title":"J Autoimmun"},{"issue":"9","key":"10.1016\/j.berh.2025.102090_bib83","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1136\/annrheumdis-2020-219511","article-title":"Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial","volume":"80","author":"Kragsnaes","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2025.102090_bib84","first-page":"1078","article-title":"Efficacy and safety of oral administration of a mixture of probiotic strains in patients with psoriasis: a randomized controlled clinical trial","volume":"99","author":"Navarro-L\u00f3pez","year":"2019","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.berh.2025.102090_bib85","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.3390\/ijms24076571","article-title":"A novel E3 probiotics formula restored gut dysbiosis and remodelled gut microbial network and microbiome dysbiosis index (MDI) in southern Chinese adult psoriasis patients","volume":"24","author":"Choy","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"13","key":"10.1016\/j.berh.2025.102090_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241311225","article-title":"Transforming psoriasis care: probiotics and prebiotics as novel therapeutic approaches","volume":"24","author":"Buha\u015f","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.berh.2025.102090_bib87","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/24755303221142296","article-title":"The role of probiotics as an adjunctive therapy in psoriasis","volume":"8","author":"Gilli","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"10.1016\/j.berh.2025.102090_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1292406","article-title":"A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasis","volume":"11","author":"Ehst","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.berh.2025.102090_bib89","article-title":"Probiotic supplements benefit psoriasis therapy rather than affecting disease risk: evidence from NHANES machine-learning and meta-analysis study","author":"Li","year":"2024","journal-title":"Probiotics Antimicrob Proteins"},{"issue":"3","key":"10.1016\/j.berh.2025.102090_bib90","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4161\/mabs.28376","article-title":"Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab","volume":"6","author":"Aira","year":"2014","journal-title":"mAbs"},{"issue":"3","key":"10.1016\/j.berh.2025.102090_bib91","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jaad.2014.01.897","article-title":"Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study","volume":"71","author":"Krupashankar","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102090_bib92","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaad.2015.03.040","article-title":"Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: a double-blind, randomized-withdrawal, placebo-controlled study","volume":"73","author":"Dogra","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"10415","key":"10.1016\/j.berh.2025.102090_bib93","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(23)01619-7","article-title":"Efficacy of rocatinlimab for moderate-to-severe atopic dermatitis","volume":"402","author":"Devjani","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.berh.2025.102090_bib94","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.berh.2025.102090_bib96","article-title":"Efficacy and safety of ixekizumab or ixekizumab concomitantly administered with tirzepatide in adult participants with moderate-to-severe plaque psoriasis and obesity or overweight: a phase 3b, randomized, multicenter, open-label study (TOGETHER-PsO)","year":"2025","journal-title":"clinicaltrials gov"},{"key":"10.1016\/j.berh.2025.102090_bib97","article-title":"Pharmacokinetics and safety of icotinib hydrochloride cream in patients with mild to moderate chronic plaque psoriasis: a randomized double-blind vehicle-controlled phase 1 study","volume":"2019","author":"Liu","year":"2019","journal-title":"BioMed Res Int"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T17:12:10Z","timestamp":1765386730000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694225000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":89,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1521694225000580"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2025.102090","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pipeline treatments on psoriatic disease","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2025.102090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102090"}}